- Home
- NTRA vs PNR Comparison
NTRA vs PNR Comparison
Compare NTRA & PNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- PNR
- Stock Information
- Founded
- NTRA 2003
- PNR 1966
- Country
- NTRA United States
- PNR United Kingdom
- Employees
- NTRA N/A
- PNR N/A
- Industry
- NTRA Medical Specialities
- PNR Industrial Machinery/Components
- Sector
- NTRA Health Care
- PNR Industrials
- Exchange
- NTRA Nasdaq
- PNR Nasdaq
- Market Cap
- NTRA 13.7B
- PNR 14.4B
- IPO Year
- NTRA 2015
- PNR N/A
- Fundamental
- Price
- NTRA $129.95
- PNR $92.31
- Analyst Decision
- NTRA Strong Buy
- PNR Buy
- Analyst Count
- NTRA 15
- PNR 15
- Target Price
- NTRA $123.64
- PNR $92.36
- AVG Volume (30 Days)
- NTRA 1.2M
- PNR 1.1M
- Earning Date
- NTRA 11-06-2024
- PNR 10-22-2024
- Dividend Yield
- NTRA N/A
- PNR 1.01%
- EPS Growth
- NTRA N/A
- PNR 33.17
- EPS
- NTRA N/A
- PNR 3.96
- Revenue
- NTRA $1,360,503,000.00
- PNR $4,109,899,999.00
- Revenue This Year
- NTRA $42.99
- PNR $0.77
- Revenue Next Year
- NTRA $13.11
- PNR $4.30
- P/E Ratio
- NTRA N/A
- PNR $23.11
- Revenue Growth
- NTRA 46.13
- PNR N/A
- 52 Week Low
- NTRA $36.90
- PNR $57.18
- 52 Week High
- NTRA $128.28
- PNR $92.03
- Technical
- Relative Strength Index (RSI)
- NTRA 66.43
- PNR 69.04
- Support Level
- NTRA $114.62
- PNR $84.61
- Resistance Level
- NTRA $118.52
- PNR $87.18
- Average True Range (ATR)
- NTRA 4.62
- PNR 1.90
- MACD
- NTRA 0.87
- PNR 0.51
- Stochastic Oscillator
- NTRA 99.77
- PNR 97.68
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About PNR Pentair plc.
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Pentair's business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.1 billion in revenue in 2023.